ArticleCureus2026
Cytogenetic Characteristics of Chronic Lymphocytic Leukemia Patients: A Single-Center Study From Morocco.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
objectiveChronic lymphocytic leukemia (CLL) is the most common adult leukemia, characterized by significant clinical and biological heterogeneity. Cytogenetic abnormalities play a crucial prognostic role and influence treatment decisions. This study aimed to characterize the cytogenetic profile of CLL patients in a Moroccan tertiary hospital and to describe the distribution of major chromosomal abnormalities. MATERIALS AND
methodsWe conducted a retrospective descriptive study including patients diagnosed with CLL between January 2023 and December 2025 in the Hematology Department. Clinical, demographic, and cytogenetic data were collected from medical records. Cytogenetic analysis was performed using conventional karyotyping and/or fluorescence in situ hybridization (FISH), according to routine availability in daily practice.
resultsA total of 53 patients were included, with a slight male predominance, comprising 28 (52.8%) men and 25 (47.2%) women, resulting in a male-to-female ratio of 1.12. The median age was 57 years, and the mean age was 56.2 years. Conventional karyotyping was performed in 20 of 53 patients (38%). Among the patients who underwent conventional karyotyping, 16 (80%) had a complex karyotype and four (20%) had a normal karyotype, corresponding to 30.2% and 7.5% of the overall cohort, respectively. FISH analysis was available for 46 (86.8%) patients and detected cytogenetic abnormalities in 24 (45.3%) patients. The most frequent abnormality was del(17p)/TP53, identified in 17 (47.2%) patients, followed by del(11q) in nine (25%) patients, del(13q14) in six (16.7%) patients, trisomy 12 in three (8.3%) patients, and del(14q) in one (2.8%) patient. Only one (2.8%) patient had an isolated 13q deletion, which is generally associated with a favorable prognosis.
conclusionCytogenetic abnormalities were frequent in this cohort, mainly TP53/17p deletion and complex karyotype. These results support routine cytogenetic assessment for accurate risk stratification and treatment planning in CLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.